Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus etoposide/cisplatin with concurrent radiotherapy in stage III non-small cell lung cancer with EGFR 19/21 Mutation, the primary endpoint is progression-free survival
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Unresectable stage IIIA / IIIB non-small cell lung cancer with EGFR 19/21 mutation
No previous systemic anticancer therapy
Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site
ECOG Performance Status of 0 to 1
You may not be if
Prior treatment with anti-EGFR (the epidermal growth factor receptor) monoclonal antibody or small molecular compounds therapy such as gefitinib, erlotinib or cetuximab
Evidence of clinically active Interstitial Lung Diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)
Known severe hypersensitivity to icotinib or any of the excipients of this product
Clareo Health | Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
